Pharmacokinetics and Biodistribution of 16,16 dimethyl Prostaglandin E2 in Non-Irradiated and Irradiated Mice and Non-Irradiated Non-Human Primates

被引:2
作者
Langevin, Brooke [1 ]
Singh, Pratibha [2 ]
Plett, P. Artur [2 ]
Sampson, Carol H. [2 ]
Masters, Andi [3 ]
Gibbs, Allison [4 ]
De Faria, Eduardo [4 ]
Triesler, Sarah [4 ]
Zodda, Andrew [4 ]
Jackson, Isabel L. [4 ]
Orschell, Christie M. [2 ]
Gopalakrishnan, Mathangi [1 ]
Pelus, Louis M. [2 ,5 ]
机构
[1] Univ Maryland, Sch Pharm, Ctr Translat Med, Baltimore, MD 21201 USA
[2] Indiana Univ Sch Med, Div Hematol Oncol, Dept Med, Indianapolis, IN 46202 USA
[3] Indiana Univ Sch Med, IU Simon Comprehens Canc Ctr, Clin Pharmacol Analyt Core, Indiana, PA 46202 USA
[4] Univ Maryland, Sch Med, Dept Radiat Oncol, Div Translat Radiat Sci, Baltimore, MD 21201 USA
[5] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA
基金
美国国家卫生研究院;
关键词
ACUTE-RADIATION-SYNDROME; HEMATOPOIETIC STEM; INCREASES SURVIVAL; H-ARS; RECOVERY; MOUSE; MODEL; E-2; LETHALITY; ANALOGS;
D O I
10.1667/RADE-23-00040.1
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Exposure to high-dose ionizing radiation can lead to lifethreatening injuries and mortality. Bone marrow is the most sensitive organ to radiation damage, resulting in the hematopoietic acute radiation syndrome (H-ARS) with the potential sequelae of infection, hemorrhage, anemia, and death if untreated. The development of medical countermeasures (MCMs) to protect or mitigate radiation injury is a medical necessity. In our well-established murine model of H-ARS we have demonstrated that the prostaglandin E2 (PGE2) analog 16,16 dimethyl-PGE2 (dmPGE2) has survival efficacy as both a radioprotectant and radiomitigator. The purpose of this study was to investigate the pharmacokinetics (PK) and biodistribution of dmPGE2 when used as a radioprotector in irradiated and non-irradiated inbred C57BL/6J mice, PK in irradiated and non-irradiated Jackson Diversity Outbred (JDO) mice, and the PK profile of dmPGE2 in non-irradiated non-human primates (NHPs). The C57BL/6J and JDO mice each received a single subcutaneous (SC) dose of 35 ug of dmPGE2 and were randomized to either receive radiation 30 min later or remain non-irradiated. Plasma and tissue PK profiles were established. The NHP were dosed with 0.1 mg/kg by SC administration and the PK profile in plasma was established. The concentration time profiles were analyzed by standard non-compartmental analysis and the metrics of AUC0-Inf, AUC60- 480 (AUC from 60-480 min), Cmax, and t1/ 2 were evaluated. AUC60- 480 represents the postirradiation time frame and was used to assess radiation effect. Overall, AUC0-Inf, Cmax, and t1/ 2 were numerically similar between strains (C57BL/AUC0-Inf: 112.50 ngh/ml and 114.48 ngh/ml, Cmax: 44.53 ng/ ml and 63.96 ng/ml; t1/2: 1.8 h and 1.1 h, respectively). PK metrics were numerically lower in irradiated C57BL/6J mice than in non-irradiated mice [irradiation ratio: irradiated values/ non-irradiated values 1/4 0.71 for AUC60- 480 (i.e., 29% lower), and 0.6 for t1/2]. In JDO mice, the radiation ratio was 0.53 for AUC60- 480 (i.e., 47% lower), and 1.7 h for t1/2. The AUC0- Inf, Cmax, and t1/ 2 of the NHPs were 29.20 ngh/ml, 7.68 ng/ml, and 3.26 h, respectively. Despite the numerical differences seen between irradiated and non-irradiated groups in PK parameters, the effect of radiation on PK can be considered minimal based on current data. The biodistribution in C57BL/6J mice showed that dmPGE2 per gram of tissue was highest in the lungs, regardless of exposure status. The radiation ratio for the different tissue AUC60- 480 in C57BL/6J mice ranged between 0.5-1.1 (50% lower to 10% higher). Spleen, liver and bone marrow showed close to twice lower exposures after irradiation, whereas heart had a 10% higher exposure. Based on the clearance values from mice and NHP, the estimated allometric scaling coefficient was 0.81 (95% CI: 0.75, 0.86). While slightly higher than the current literature estimates of 0.75, this scaling coefficient can be considered a reasonable estimate and can be used to scale dmPGE2 dosing from animals to humans for future trials. 2024 by Radiation Research Society
引用
收藏
页码:7 / 18
页数:12
相关论文
共 41 条
[1]   UPTAKE AND INACTIVATION OF PROSTAGLANDIN-E-2 METHYL ANALOGS IN RAT PULMONARY CIRCULATION [J].
BAKHLE, YS ;
JANCAR, S ;
WHITTLE, BJR .
BRITISH JOURNAL OF PHARMACOLOGY, 1978, 62 (02) :275-280
[2]   The Role of PGE2 in Alveolar Epithelial and Lung Microvascular Endothelial Crosstalk [J].
Barnthaler, Thomas ;
Maric, Jovana ;
Platzer, Wolfgang ;
Konya, Viktoria ;
Theiler, Anna ;
Hasenohrl, Carina ;
Gottschalk, Benjamin ;
Trautmann, Sandra ;
Schreiber, Yannick ;
Graier, Wolfgang F. ;
Schicho, Rudolf ;
Marsche, Gunther ;
Olschewski, Andrea ;
Thomas, Dominique ;
Schuligoi, Rufina ;
Heinemann, Akos .
SCIENTIFIC REPORTS, 2017, 7
[3]   Ways to fit a PK model with some data below the quantification limit [J].
Beal, SL .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (05) :481-504
[4]   Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule [J].
Bergman, Kimberly L. ;
Krudys, K. ;
Seo, S. K. ;
Florian, J. .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (02) :153-160
[6]   Lifelong Residual bone Marrow Damage in Murine Survivors of the Hematopoietic Acute Radiation Syndrome (H-ARS): A Compilation of Studies Comprising the Indiana University Experience [J].
Chua, Hui Lin ;
Plett, P. Artur ;
Fisher, Alexa ;
Sampson, Carol H. ;
Vemula, Sasidhar ;
Feng, Hailin ;
Sellamuthu, Rajendran ;
Wu, Tong ;
MacVittie, Thomas J. ;
Orschell, Christie M. .
HEALTH PHYSICS, 2019, 116 (04) :546-557
[7]  
Coleman C. Norman, 2003, Radiation Research, V159, P812, DOI 10.1667/RR3021
[8]  
Constine LS, 1988, Radiobiology in Radiotherapy, P95, DOI [10.1007/978-1-4471-1603-5_10, DOI 10.1007/978-1-4471-1603-5_10]
[9]  
Dainiak Nicholas, 2003, Hematology Am Soc Hematol Educ Program, P473
[10]   EFFECT OF INTRAVENTRICULARLY ADMINISTERED PROSTAGLANDIN-E1 ON ELECTRICAL-ACTIVITY OF CEREBRAL-CORTEX AND BEHAVIOR IN UNANESTHETIZED MONKEY [J].
DESIRAJU, T .
PROSTAGLANDINS, 1973, 3 (06) :859-870